Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
Pivotal Phase 3 study, NANORAY-312, actively enrolling elderly, LA-HNSCC patients ineligible for cisplatin across ~50 sites as LianBio enrolls first patient and continues to ramp...
